Expression Therapeutics Inc., a clinical-stage biopharmaceutical company developing next-generation cellular therapies, has appointed David F. Townson, Ph.D., as Chief Executive Officer, effective ...
TERN-701 more than doubled the response rate of Novartis’ rival approved therapy in an early-stage trial, sending the biotech ...
At the heart of the deal is Relation’s Lab-in-the-Loop platform, which uses AI models to improve understanding of diseases ...
Through “My Cause My Cleats,” Tyler Smith raises cancer awareness with survivor-designed cleats and a personal tribute to his ...
New NATALEE 5-year sub-analysis data reinforce sustained reduction in distant disease-free survival in broadest population of EBC patients13 ...
3d
Relation announces strategic collaboration with Novartis to advance therapeutics for atopic diseases
The collaboration pairs Relation’s AI-powered drug discovery platform and human data generation capabilities with Novartis’s deep expertise in immuno-dermatology to identify, validate, and advance ...
Novartis has tapped up an AI-enabled British biotech for a $1.7 billion biobucks deal to discover new targets for ...
Relation Therapeutics Ltd. will collaborate with Novartis AG in a $1.7 billion deal to develop multiple programs to find and advance targets for treating atopic diseases caused by immune dysregulation ...
Cuban attributes the US’ high drug prices to PBMs—often considered the “middlemen” within the pharma supply chain—arguing ...
Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy December 1, 2025 10:00 AM ESTCompany ...
Monte Rosa Therapeutics is transitioning from an oncology focus to a next-gen immunology & inflammation platform. Read why ...
Since launching in 2024, Novartis Canada is proud to have awarded over $1.2 million in funding through the Health Equity Initiative to drive meaningful and sustainable projects that will support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback